216 related articles for article (PubMed ID: 34885186)
1. SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma.
Mynarek M; Milde T; Padovani L; Janssens GO; Kwiecien R; Mosseri V; Clifford SC; Doz F; Rutkowski S
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885186
[TBL] [Abstract][Full Text] [Related]
2. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
3. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial.
Bailey S; André N; Gandola L; Massimino M; Wheatley K; Gates S; Homer V; Rutkowski S; Clifford SC
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053536
[TBL] [Abstract][Full Text] [Related]
4. Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts.
Mynarek M; Obrecht D; Sill M; Sturm D; Kloth-Stachnau K; Selt F; Ecker J; von Hoff K; Juhnke BO; Goschzik T; Pietsch T; Bockmayr M; Kool M; von Deimling A; Witt O; Schüller U; Benesch M; Gerber NU; Sahm F; Jones DTW; Korshunov A; Pfister SM; Rutkowski S; Milde T
Acta Neuropathol; 2023 Jan; 145(1):97-112. PubMed ID: 36459208
[TBL] [Abstract][Full Text] [Related]
5. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC; Lindsey JC; Nakjang S; Crosier S; Smith AJ; Hicks D; Rafiee G; Hill RM; Iliasova A; Stone T; Pizer B; Michalski A; Joshi A; Wharton SB; Jacques TS; Bailey S; Williamson D; Clifford SC
Lancet Oncol; 2017 Jul; 18(7):958-971. PubMed ID: 28545823
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma : First experiences of the German radiotherapy quality control panel in the SIOP PNET5 MB trial.
Dietzsch S; Braesigk A; Seidel C; Remmele J; Kitzing R; Schlender T; Mynarek M; Geismar D; Jablonska K; Schwarz R; Pazos M; Walser M; Frick S; Gurtner K; Matuschek C; Harrabi SB; Glück A; Lewitzki V; Dieckmann K; Benesch M; Gerber NU; Rutkowski S; Timmermann B; Kortmann RD
Strahlenther Onkol; 2021 Aug; 197(8):674-682. PubMed ID: 33226469
[TBL] [Abstract][Full Text] [Related]
7. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial.
Clifford SC; Lannering B; Schwalbe EC; Hicks D; O'Toole K; Nicholson SL; Goschzik T; Zur Mühlen A; Figarella-Branger D; Doz F; Rutkowski S; Gustafsson G; Pietsch T;
Oncotarget; 2015 Nov; 6(36):38827-39. PubMed ID: 26420814
[TBL] [Abstract][Full Text] [Related]
8. A dedicated cloud system for real-time upfront quality assurance in pediatric radiation therapy.
Meroni S; Cavatorta C; Barra S; Cavagnetto F; Scarzello G; Scaggion A; Pecori E; Diletto B; Alessandro O; Massimino M; Gianolini S; Pignoli E; Gandola L
Strahlenther Onkol; 2019 Sep; 195(9):843-850. PubMed ID: 31025053
[TBL] [Abstract][Full Text] [Related]
9. Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial.
Dietzsch S; Braesigk A; Seidel C; Remmele J; Kitzing R; Schlender T; Mynarek M; Geismar D; Jablonska K; Schwarz R; Pazos M; Weber DC; Frick S; Gurtner K; Matuschek C; Harrabi SB; Glück A; Lewitzki V; Dieckmann K; Benesch M; Gerber NU; Obrecht D; Rutkowski S; Timmermann B; Kortmann RD
Strahlenther Onkol; 2022 Mar; 198(3):282-290. PubMed ID: 34351451
[TBL] [Abstract][Full Text] [Related]
10. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
[TBL] [Abstract][Full Text] [Related]
11. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271
[TBL] [Abstract][Full Text] [Related]
12. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
[TBL] [Abstract][Full Text] [Related]
13. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
[TBL] [Abstract][Full Text] [Related]
14. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
[TBL] [Abstract][Full Text] [Related]
15. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II.
Bailey CC; Gnekow A; Wellek S; Jones M; Round C; Brown J; Phillips A; Neidhardt MK
Med Pediatr Oncol; 1995 Sep; 25(3):166-78. PubMed ID: 7623725
[TBL] [Abstract][Full Text] [Related]
16. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
[TBL] [Abstract][Full Text] [Related]
17. WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?
Mani S; Chatterjee A; Dasgupta A; Shirsat N; Epari S; Chinnaswamy G; Gupta T
Oncotarget; 2023 Feb; 14():105-110. PubMed ID: 36749287
[TBL] [Abstract][Full Text] [Related]
18. Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.
Lucas JT; Tinkle CL; Huang J; Onar-Thomas A; Srinivasan S; Tumlin P; Becksfort JB; Klimo P; Boop FA; Robinson GW; Orr BA; Harreld JH; Krasin MJ; Northcott PA; Ellison DW; Gajjar A; Merchant TE
Neuro Oncol; 2022 Jul; 24(7):1166-1175. PubMed ID: 34894262
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters.
von Bueren AO; Kortmann RD; von Hoff K; Friedrich C; Mynarek M; Müller K; Goschzik T; Zur Mühlen A; Gerber N; Warmuth-Metz M; Soerensen N; Deinlein F; Benesch M; Zwiener I; Kwiecien R; Faldum A; Bode U; Fleischhack G; Hovestadt V; Kool M; Jones D; Northcott P; Kuehl J; Pfister S; Pietsch T; Rutkowski S
J Clin Oncol; 2016 Dec; 34(34):4151-4160. PubMed ID: 27863192
[TBL] [Abstract][Full Text] [Related]
20. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL
Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
